HETEROCYCLIC COMPOUNDS
A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L′ are suitable leaving groups, with a compound of formula (III) UNH 2 (III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R 1 by replacement of the leaving group L′.
1 . A method of inhibiting EGFR in a mammal subject, comprising administering to said mammal an effective amount of a compound of the formula:
or salts or solvates thereof.
2 . A method as claimed in claim 1 , wherein the mammal is a human.
3 . A method as claimed in claim 1 , wherein the mammal is a human suffering from a cancer exhibiting aberrant EGFR activity.
4 . A method of inhibiting c-erbB-2 in a mammal subject, comprising administering to said mammal an effective amount of a compound of the formula:
or salts or solvates thereof.
5 . A method as claimed in claim 4 , wherein the mammal is a human.
6 . A method as claimed in claim 4 , wherein the mammal is a human suffering from a cancer exhibiting aberrant c-erbB-2 activity.
7 . A method of inhibiting EGFR and c-erbB-2 in a mammal subject, comprising administering to said mammal an effective amount of a compound of the formula:
or salts or solvates thereof.
8 . A method as claimed in claim 7 , wherein the mammal is a human.
9 . A method as claimed in claim 7 , wherein the mammal is a human suffering from a cancer exhibiting aberrant EGFR and c-erbB-2 activity.